BEGACESTAT

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C9H8ClF6NO3S2
Molecular Weight	391.738
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC[C@@H](NS(=O)(=O)C1=CC=C(Cl)S1)C(C(F)(F)F)C(F)(F)F

InChI

InChIKey=PSXOKXJMVRSARX-SCSAIBSYSA-N

InChI=1S/C9H8ClF6NO3S2/c10-5-1-2-6(21-5)22(19,20)17-4(3-18)7(8(11,12)13)9(14,15)16/h1-2,4,7,17-18H,3H2/t4-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C9H8ClF6NO3S2
Molecular Weight	391.738
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.pfizer.com/sites/default/files/research/pipeline/2010_0927/pipeline_2010_0927.pdf |

Begacestat (GSI-953 or PF-5212362), a gamma-secretase inhibitor (GSI) that selectively inhibits cleavage of APP over Notch, was discovered for the treatment of Alzheimer's disease. The drug has shown promise results in phase I clinical trials, however further studies were discontinued.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Gamma-secretase 21 Target ID: CHEMBL2094135 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19671883	Inhibitor 8297		8.0 nM [IC50]

PubMed

Title	Date	PubMed
		252160745
Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease.	2008 Dec 11	19012391
Biological markers for early detection and pharmacological treatment of Alzheimer's disease.	2009	19585950
[Alzheimer's disease treatment by inhibition/modulation of the gamma-secretase activity].	2009 Nov	20030227
Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.	2009 Nov	19671883
Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease.	2010 Dec 29	21190552
Clinical trials in CNS--SMi's eighth annual conference.	2010 Feb	20127552
Brain amyloid β protein and memory disruption in Alzheimer's disease.	2010 Sep 7	20856923

Patents

Sample Use Guides

In Vivo Use Guide

Oral capsule, 10- and 50-mg, either once a day for 14 days or twice a day for 14 days, depending on cohort assignment.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:05:55 GMT 2023` Edited by `admin` on `Fri Dec 15 16:05:55 GMT 2023`
Record UNII	3666C56BBU
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BEGACESTAT

Official Name

English

begacestat [INN]

Common Name

English

GSI-953

Code

English

5-Chloro-N-[(1S)-3,3,3-trifluoro-1-(hydroxymethyl)-2-(trifluoromethyl)propyl]thiophene-2-sulfonamide

Systematic Name

English

2-THIOPHENESULFONAMIDE, 5-CHLORO-N-((1S)-3,3,3-TRIFLUORO-1-(HYDROXYMETHYL)-2-(TRIFLUOROMETHYL)PROPYL)-

Systematic Name

English

BEGACESTAT [USAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C783